Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Share

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

“Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex.

“CFTR modulators have already revolutionized the way we treat CF and I am encouraged that, if approved, this medicine could advance CF treatment even further,” said Professor Marcus A. Mall, M.D., Professor and Chair of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center at Charité - Universitätsmedizin Berlin. “The results we saw from the two deutivacaftor/tezacaftor/vanzacaftor Phase 3 clinical trials were motivating as they showed non-inferiority in ppFEV1 and superior improvement of sweat chloride levels compared to ivacaftor/tezacaftor/elexacaftor in combination with ivacaftor.”

ALYFTREK® is currently licensed in the U.S. and UK and is under regulatory review in Canada, Switzerland, Australia and New Zealand.

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving.

Today Vertex CF medicines are treating over 68,000 people with CF across more than 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy.

Diagnosis of CF is often made by genetic testing and is confirmed by testing sweat chloride (SwCl), which measures CFTR protein dysfunction. The diagnostic threshold for CF is SwCl ≥60 mmol/L, while levels between 30-59 indicate CF is possible and more testing may be needed to make the diagnosis of CF. A SwCl level of <30 mmol/L is seen in people who carry one copy of a CFTR gene mutation but do not have any manifestation of disease (carriers). At a population level, higher levels of SwCl are associated with more severe disease. Restoring CFTR function leads to lower levels of SwCl. SwCl levels below 60 mmol/L are associated with improved outcomes such as better and more stable lung function, fewer pulmonary exacerbations, better quality of life and improved survival. Restoring SwCl levels below 30 mmol/L has long been the ultimate treatment goal for Vertex, as levels below 30 mmol/L are considered normal and are typical of CF carriers who do not have disease.

About ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor)

In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Carmen Bozic, M.D., and Professor Marcus A. Mall, M.D., in this press release, statements regarding the expected eligible patient population for ALYFTREK, if approved, and statements regarding the potential benefits of ALYFTREK. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that regulatory authorities in the EU may not approve ALYFTREK on a timely basis or at all, and other risks listed under the heading “Risk Factors” in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com and www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20250427155116/en/

Contacts

Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com

Media:
mediainfo@vrtx.com
or
International: +44 20 3204 5275

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quant Makes Money Smarter With Rollout of Industry-Wide Programmable Money22.5.2025 11:07:00 EEST | Press release

Quant, a global leader in fintech and innovation, today announces the rollout of Quant Flow, an industry-first programmable money and banking infrastructure now available via a white-label solution to banks, institutions and corporates across Europe, the Middle East, and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522277808/en/ Gilbert Verdain, CEO of Quant Quant Flow was developed in response to the growing demand for smarter forms of commercial bank money and the need to modernise financial infrastructure, driven by rising regulatory pressure and competition from stablecoins, central bank digital currencies (CBDCs), neobanks and fintechs. Quant Flow delivers automation and intelligence directly into money at the account level. For banks, this means they can respond to market demand, address regulation, innovate with new forms of money and defend profitability – all without the need for costly system overhauls.

Manchester City Puts Smart Water Tech in Play on the Pitch22.5.2025 11:00:00 EEST | Press release

Manchester City Football Club is using data and analytics for more than performance on the pitch. A champion of water sustainability, the Club is taking its commitment to the next level – introducing digital solutions from its official water technology partner, Xylem (NYSE: XYL), to help capture and reuse rainwater more efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522922860/en/ Manchester City Football Club is teaming up with Xylem to bring smart water management to City Football Academy. With the help of Xylem Vue, the Club is capturing and reusing rainwater more efficiently through data and analytics. At City Football Academy, Xylem Vue – a digital water platform – uses connected sensors and smart meters to deliver live insights into how water moves across the training facility. Showing exactly when and where water is being used or lost across the 16.5-pitch campus, the system helps the Club make smarter

Pure Lithium and E3 Lithium Report Results From Phase 1 of the Lithium Metal Battery Joint Development Agreement22.5.2025 10:15:00 EEST | Press release

Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce initial results from the battery cells manufactured under the Joint Development Agreement with E3 Lithium, using E3 Lithium’s brines and DLE technology and Pure Lithium’s innovative extraction and battery technology. Several variations of E3’s lithium chloride concentrate were used to make lithium metal anodes at Pure Lithium’s Boston facility. The lithium from the E3 concentrated lithium chloride was electrodeposited as pure lithium metal onto a copper substrate, creating a complete, battery ready anode. These anodes were then assembled by Pure Lithium into batteries, and their electrochemical performance was evaluated in full cells. Notable results include: Lithium Metal Purity: The various E3 brine streams all achieved a very high purity level, > 99.9% pure lithium metal as tested by ICP-OES analysis. Cell Performance (Life Cycle): This tests for the number o

Manhattan Associates Unveils Agentic AI Innovation at Momentum 202522.5.2025 10:00:00 EEST | Press release

Kicking off Momentum 2025, Manhattan Associates Inc. (NASDAQ: MANH) today announced sweeping Agentic AI support within Manhattan Active® solutions that includes intelligent, autonomous digital agents to revolutionise supply chain commerce execution, optimisation, and user experiences. These out-of-the-box AI agents, powered by large language models (LLMs) and Manhattan’s cloud-native, all-microservice API architecture, will autonomously perform tasks, adapt to changing conditions, and dynamically orchestrate workflows. This breakthrough marks a generational leap from traditional chatbots and static workflow configurations to dynamic, intelligent, and situationally aware orchestration across the entire supply chain and commerce lifecycle. Among the first groundbreaking AI agents announced are the Intelligent Store Manager, Labor Optimizer Agent, Wave Inventory Research Agent, Contextual Data Assistant, and Virtual Configuration Consultant. These digital agents allow users to interact wi

Empowering Local Industry: SFI Health ™ EMEA Commits to South African Packing Operations22.5.2025 09:30:00 EEST | Press release

SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce that the packing of its branded products in South Africa will be now fully managed locally leveraging local talent and facilities. The company is known for its clinically researched products in microbiome, cognition, and well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521282786/en/ This initiative enhances SFI Health South Africa’s ability to offer greater flexibility in pack sizes, ensuring a product portfolio that aligns more closely with the needs of South African consumers. By taking this step, the company aims to make its scientifically supported health solutions more accessible, without compromising on quality or efficacy. Simultaneously, this initiative will have a positive ripple effect on the local economy: all packaging materials will be sourced from South African suppliers, and the produc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye